Clinical trials: First Line Treatment
Mantle Cell Lymphoma, Non-Hodgkin's Lymphoma
A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL).
A study to evaluate the efficacy of lenalidomide as maintenance therapy after completion of first-line combination chemotherapy in patients with mantle cell lymphoma (MCL) who are not candidates for transplantation and have…
- Trial name
- RENEW (NCT01021423)
- Testing
- Lenalidomide
- Where
- 92 sites in United States, Czechia and 10 more
- Volunteers
- 9 people
- Sponsor
- Celgene
Lung Adenocarcinoma, Cryotherapy Effect
Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma
This study aims to compare the one-year survival benefit of the association of cryoablation-pembrolizumab-pemetrexed-carboplatin versus pembrolizumab-pemetrexed-carboplatin in metastatic lung adenocarcinoma patients.
- Trial name
- CRYOMUNE (NCT04339218)
- Testing
- Cryoablation, Pembrolizumab, Pemetrexed
- Where
- France
- Volunteers
- 214 people
- Sponsor
- Institut Bergonié
Hepatocellular Carcinoma, Oligoprogression
Second-line Systemic Therapy Combined with SBRT for HCC with Oligoprogression After Standard First-line Systemic Treatment
Approximately 70% of hepatocellular carcinoma (HCC) patients are diagnosed at an advanced stage, with no opportunity for curative treatments. For these patients, systemic therapies are the main treatment modalities.
- Trial name
- NCT06592612
- Testing
- SBRT and second-line systemic therapy, Second-line systemic therapy
- Volunteers
- 70 people
- Sponsor
- Sun Yat-sen University
Immune Thrombocytopenic Purpura (ITP)
A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP
The purpose of this trial was to assess the ability of eltrombopag to induce sustained treatment-free remission in immune thrombocytopenia purpura (ITP) subjects who relapsed or failed to respond to an initial treatment with…
- Trial name
- TAPER (NCT03524612)
- Testing
- eltrombopag
- Where
- 32 sites in United States, Austria and 13 more
- Volunteers
- 105 people
- Sponsor
- Novartis Pharmaceuticals
Prostatic Neoplasms
Continued Treatment With Docetaxel Versus Switch to Cabazitaxel After Minor Prostate Specific Antigen Response to Docetaxel in Patients With Castration-Resistant Metastatic Prostate Cancer
Primary Objective: To compare the continuation of treatment with docetaxel versus switching to cabazitaxel regarding the time to PSA (Prostatic Specific Antigen) progression (TTP-PSA), in patients with Castration-Resistant…
- Trial name
- SWITCH (NCT01576029)
- Testing
- CABAZITAXEL (XRP6258), DOCETAXEL (XRP6976)
- Where
- 8 sites in Brazil
- Volunteers
- 2 people
- Sponsor
- Sanofi
Non-small Cell Lung Cancer (NSCLC)
A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETY
This is a study of brigatinib in adults with Non-Small Cell Lung Cancer (NSCLC). The main aim of this study is to learn about the time period in which the condition does not worsen after the participant has received brigatinib.
- Trial name
- ENTIRETY (NCT05735327)
- Testing
- No intervention
- Where
- 12 sites in Poland
- Volunteers
- 50 people
- Sponsor
- Takeda
Breast Cancer
A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment
This is a non-interventional observational study conducted in Germany to evaluate the real-world effectiveness, tolerability, safety, and quality of life in patients with locally advanced/metastatic HR+/HER2- breast cancer…
- Trial name
- RIBANNA (NCT06311383)
- Testing
- First-line Ribociclib + endocrine therapy, First-line endocrine therapy, First-line chemtherapy
- Where
- 265 sites in Germany
- Volunteers
- 2,610 people
- Sponsor
- Novartis Pharmaceuticals
Hepatocellular Carcinoma, Transcatheter Arterial ChEmoembolization
Regorafenib Alone or in Combined With Transcatheter Arterial ChEmoembolization in Treatment of Advanced Hepatocellular Carcinoma After First Line Targeted Therapy
. 1 Clarify the difference in efficacy of regofinib combined with TACE compared with second-line treatment of advanced liver cancer; 2.
- Conditions
- Hepatocellular Carcinoma, Transcatheter Arterial ChEmoembolization, Regorafenib
- Trial name
- ROSE (NCT05811481)
- Testing
- TACE, Regorafenib
- Where
- China
- Volunteers
- 192 people
- Sponsor
- WenBo Guo
Ankylosing Spondylitis, Axial Spondyloarthritis
Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1)
The primary objective of this study was to assess the proportion of participants in the infliximab plus naproxen arm versus the placebo plus naproxen arm, in a population of participants with moderate-to-severe active axial…
- Trial name
- INFAST (NCT00844805)
- Testing
- Infliximab, Naproxen
- Volunteers
- 158 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Myeloid Leukemia
A Trial of CPX-351 Lower Intensity Therapy (LIT) Plus Venetoclax as First Line Treatment for Subjects With AML
Study CPX351-103 is an open-label, multicenter, phase 1b, safety and PK study to determine the MTD of the combination of CPX 351 and venetoclax when administered to subjects with newly diagnosed AML who are unfit for intensive…
- Trial name
- NCT04038437
- Testing
- CPX-351, Venetoclax
- Where
- 8 sites in United States
- Volunteers
- 35 people
- Sponsor
- Jazz Pharmaceuticals
Ovulation Induction, Polycystic Ovary Syndrome
Myo-inositol Versus Clomiphene Citrate in PCOS
Specific aim: To compare inositol and the golden standard first line treatment of ovulation induction, namely clomiphene citrate.
- Conditions
- Ovulation Induction, Polycystic Ovary Syndrome, Clomiphene, Inositol
- Trial name
- NCT04306692
- Testing
- Myo-inositol, Clomiphene Citrate
- Where
- Belgium
- Volunteers
- 12 people
- Sponsor
- University Hospital, Ghent
Metastatic Breast Cancer, Triple Negative Breast Cancer
Atezolizumab Plus CArboplatin Plus Nab-paclitaxel
Primary objective: To provide preliminary evidence on the efficacy of atezolizumab plus carboplatin plus paclitaxel as first-line therapy in metastatic triple-negative PD-L1 positive breast cancer patients as evaluated by %…
- Conditions
- Metastatic Breast Cancer, Triple Negative Breast Cancer, PD-L1 Gene Mutation
- Trial name
- NCT05266937
- Testing
- Atezolizumab,Paclitaxel, Carboplatin
- Where
- 15 sites in Italy
- Volunteers
- 49 people
- Sponsor
- Consorzio Oncotech
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
The purpose of this study is to compare effectiveness of TAK-788 as first-line treatment with that of platinum-based chemotherapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors…
- Trial name
- NCT04129502
- Testing
- TAK-788, Pemetrexed, Cisplatin
- Where
- 134 sites in United States, Australia and 22 more
- Volunteers
- 354 people
- Sponsor
- Takeda
Carcinoma, Non-Small-Cell Lung
Osimertinib In EGFR Mutant Lung Cancer
This research study is studying a targeted therapy as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation. The names of the study drug involved in this study is: Osimertinib (Tagrisso)
- Trial name
- NCT03586453
- Testing
- Osimertinib
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Dana-Farber Cancer Institute
Colorectal Cancer
Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
The primary objective of this study is to compare the additive efficacy of SIM versus placebo in combination with leucovorin (folinic acid), irinotecan, and fluorouracil (FOLFIRI) as measured by improvement in progression-free…
- Trial name
- NCT01479465
- Testing
- Simtuzumab, Leucovorin, Irinotecan
- Where
- 109 sites in United States, France and 5 more
- Volunteers
- 266 people
- Sponsor
- Gilead Sciences
SCLC, Extensive Stage, Toripalimab
Real-World Study of Toripalimab in Extensive-Stage Small Cell Lung Cancer
This is a prospective, observational, multi-center, real-world study evaluating the effectiveness and safety of Toripalimab (a PD-1 inhibitor) as first-line treatment for patients with extensive-stage small cell lung cancer…
- Trial name
- NCT07308379
- Testing
- Toripalimab
- Volunteers
- 1,200 people
- Sponsor
- Fudan University
Pancreatic Cancer
Fluorouracil, External-Beam Radiation Therapy, and Gemcitabine With or Without Brachytherapy Using Phosphorus P32 in Treating Patients With Locally or Regionally Advanced Unresectable Adenocarcinoma of the Pancreas
RATIONALE: Drugs used in chemotherapy, such as fluorouracil and gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00079365
- Testing
- fluorouracil, gemcitabine hydrochloride, brachytherapy
- Where
- United States
- Sponsor
- University of South Florida
Locally Advanced Head and Neck Squamous Cell Carcinoma
Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC
First-line treatment of locally advanced HNSCC with double checkpoint blockade and radiotherapy dependent on intratumoral CD8+ T cell Infiltration.
- Trial name
- NCT03426657
- Testing
- Durvalumab + Tremelimumab + RT
- Where
- 7 sites in Germany
- Volunteers
- 120 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Hepatocellular Carcinoma
A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC)
This is a multi-center,open-label study to evaluate the efficacy and safety of anti-PD-1 antibody AK105 plus anlotinib hydrochloride in the first-line treatment of patients with unresectable hepatocellular carcinoma.
- Trial name
- NCT04172571
- Testing
- AK105, Anlotinib Hydrochloride
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Akeso
Gastric Cancer
Telatinib in Combination With Capecitabine/ Oxaliplatin in 1st Line Gastric or GEJ Cancer
The purpose of the trial is to compare the combination regimen of Telatinib and Capecitabine and Oxaliplatin vs. Capecitabine and Oxaplatin to explore superiority of the Telatinib combination in terms of progression-free survival…
- Trial name
- NCT03817411
- Testing
- Telatinib, Capecitabine, Oxaliplatin
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Taizhou EOC Pharma Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.